Dokuz Eylül University

Running trials

• Not yet recruiting

  QIPB vs SI-FICB for Postoperative Analgesia After Total Hip Arthroplasty

  NCT07683663· Dokuz Eylul University· Source

• Recruiting

  Extracorporeal Shock Wave Therapy in the Treatment of Periarticular Bone Marrow Edema in Patients With Knee Osteoarthritis

  NCT07887893· Dokuz Eylul University· Source

• Recruiting

  Tele-assessment and Face-to-face Assessment of the 30-second Sit-stand Test in Peripheral Artery Disease

  NCT07497360· Izmir Democracy University· Source

• Recruiting

  Speech-based Assessment of Relapse Risk in People With Psychosis

  NCT07397975· Philipp Homan· Source

• Active, not recruiting

  The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors

  NCT07205965· Dokuz Eylul University· Source

• Not yet recruiting

  Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer

  NCT06823297· Turkish Society of Colon and Rectal Surgery· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Endoscopic Submucosal Dissection vs. Transanal Endoscopic Surgery for Rectal Neoplasia

  NCT06902701· Turkish Society of Colon and Rectal Surgery· Source

• Recruiting

  Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue

  NCT07040657· Dokuz Eylul University· Source

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Active, not recruiting

  Online Diabetic Foot Support Program- Care Kit

  NCT06760416· Merve GÃnbaAY· Source

• Active, not recruiting

  Hypoglycemia Prevention and Awareness Program

  NCT06775288· Merve DerviAYoAYlu· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Enrolling by invitation

  Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery

  NCT06774170· Dokuz Eylul University· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

  NCT05152147· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· Phase 1/2· BeOne Medicines· Source

• Active, not recruiting

  Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT04666038· Phase 3· Loxo Oncology, Inc.· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

  NCT04166565· Phase 2· Stichting European Myeloma Network· Source

• Active, not recruiting

  Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

  NCT03711032· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

  NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Osteoarthritis2 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Mantle cell lymphoma1 recruiting
• Myasthenia gravis1 recruiting
• Pancreatic cancer1 recruiting
• Peripheral artery disease1 recruiting
• Schizophrenia1 recruiting
• Type 2 diabetes1 recruiting

Researchers

• KCKübra Canaslan

Closed trials

• Completed

  The Effect of a ChatGPT-Supported Online Group-Guided Self-Help Program on Uncontrolled and Emotional Eating Behaviors and Body Image in Overweight and Obese Woman Nurses

  NCT06653673· Dokuz Eylul University· Source

• Completed

  Reliability of BASDAI and BASFI Applied by Tele-Assessment Method in Axial SpA Spondyloarthritis

  NCT06230952· Siirt University· Source

• Completed

  Online Diabetes Clinic Support Program

  NCT06767865· Dilek Büyükkaya Besen· Source

• Completed

  Acute Responses of Active Video Games and Traditional Exercise Program in in Patients With Pulmonary Hypertension

  NCT05901168· Dokuz Eylul University· Source

• Completed

  Early-phase Exercise-based Cardiac Rehabilitation After MI

  NCT06924034· Dokuz Eylul University· Source

• Completed

  Validity and Reliability of 30SFPW Test Patients With TKA

  NCT06202170· Dokuz Eylul University· Source

• Completed

  Lifestyle Change in Women With Polycystic Ovary Syndrome

  NCT05377021· Dokuz Eylul University· Source

• Completed

  The Effects of Exercise on Gait Characteristics, Balance, and Performance in Patients With Normal Pressure Hydrocephalus

  NCT05679934· Dokuz Eylul University· Source

• Completed

  Investigation of the Effects of Family-Focused Therapy in the Early Period of Bipolar Disorder and Psychotic Disorder

  NCT05809193· Dokuz Eylul University· Source

• Completed

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Yoga and Aerobic Exercise in Epilepsy

  NCT05066880· Dokuz Eylul University· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Bipolar disorder25 works · 1 trial
• Ankylosing spondylitis11 works · 1 trial
• Neuroblastoma10 works · 0 trials
• Hepatitis B9 works · 0 trials
• Hypothyroidism8 works · 0 trials
• Coeliac disease5 works · 0 trials
• Graves' disease and hyperthyroidism5 works · 0 trials
• Lewy body dementia4 works · 0 trials